Immutep Ltd. (IMM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Immutep Ltd. (IMM)
Company Performance

Current Price

as of Oct 16, 2024

$0.20

P/E Ratio

N/A

Market Cap

$296.31M

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Metrics

Overview

  • HQSydney, NS
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMM
  • Price$0.204022-3.56%

Trading Information

  • Market Cap$296.31M
  • Float97.64%
  • Average Daily Volume (1m)7,219,769
  • Average Daily Volume (3m)5,348,897
  • EPS-$0.04

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$42.72M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$48.14M
  • EV$174.03M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B2.34
Documents
Factset
Factset Business Description
Factset Street Account
Immutep reports Q1 net cash from / (used in) operating activities (A$12.9M) - Appendix 4C (A$0.32, 0.00) (2023-10-30T21:45:33Z)
Immutep reports median overall survival reaches 35.5 months in TACTI-002 phase II trial; to hold webcast at 0800 AEDT (A$0.28, 0.00) (2023-10-22T20:57:49Z)
Immutep reports biomarker data from the TACTI-002 Phase II trial evaluating efti in combination with KEYTRUDA for patients with NSCLC (A$0.30, 0.00) (2023-11-02T21:29:13Z)
Immutep receives A$1.1M Australian Federal Government R&D tax incentive (A$0.32, -0.01) (2023-10-24T23:58:15Z)
Immutep management provides outlook, reports clinical data from INSIGHT-003 Trial at ESMO (A$0.33, 0.00) (2023-10-23T21:22:57Z)
Immutep expands INSIGHT-003 Phase I trial to four sites across Germany; expects to complete recruitment in H1 CY24 (A$0.29, 0.00) (2023-11-22T01:37:15Z)
Immutep completes safety lead-in and opening of randomized phase ii of the AIPAC-003 phase ii/iii trial in metastatic breast cancer (A$0.30, 0.00) (2023-11-05T21:33:01Z)
Immutep completes enrolment for TACTI-003 Phase IIb trial of efti and keytruda in first line metastatic HNSCC (A$0.30, 0.00) (2023-11-08T21:40:15Z)
Wikipedia
Immutep_Ltd